Search / Trial NCT00002297

A Study of Isoprinosine in Patients With Lymph Node Disease

Launched by NEWPORT PHARMACEUTICALS INTERNATIONAL · Aug 30, 2001

Trial Information

Current as of December 27, 2024

Completed

Keywords

Inosine Pranobex Aids Related Complex

ClinConnect Summary

No description provided

Gender

MALE

Eligibility criteria

  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, or gastric ulceration are excluded.
  • Concurrent Medication:
  • Excluded:
  • Systemic corticosteroids.
  • Cytotoxic immunosuppressive agents.
  • Radiotherapy.
  • Critically ill patients or those with CDC-defined AIDS are excluded.
  • Prior Medication:
  • Excluded within 1 month of study entry:
  • Immunotherapy.
  • Patients with persistent generalized lymphadenopathy (PGL).

About Newport Pharmaceuticals International

Newport Pharmaceuticals International is a leading biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs across various therapeutic areas. With a strong focus on research and development, Newport Pharmaceuticals harnesses cutting-edge science and technology to create effective treatments aimed at improving patient outcomes. The company is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring safety and efficacy while fostering collaboration with healthcare professionals and regulatory bodies. Through its dedication to innovation and excellence, Newport Pharmaceuticals International strives to make a meaningful impact on global health.

Locations

Laguna Hills, California, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials